|
Karateev A.E.
Rheumatological problems with COVID-19: from arthralgia to rheumatoid arthritis
|
№2 / 2022
|
|
Mazurov V.I., Melnikov Е.S., Bashkinov R.A.
Effect of platelets on the course of rheumatoid arthritis and cardiovascular risk
|
№10 / 2021
|
|
Eliseeva l.N., Kartashova S.V.
Mexidol® and mexidol® forte 250 in consecutive therapy of cognitive disorders in comorbid patients with joint pathology on the background of arterial hypertension and ischemic heart disease
|
№6 / 2020
|
|
Nesterovich I.I., Nochevnaya K.V., Rabik Y.D., Vasina L.V., Speranskaya A.A., Zolotnitskaya V.P., Amosov V.I., Trofimov V.I., Vlasov T.D.
Signs of pulmonary damage according to X-ray examinations data in rheumatic arthritis patients with different serological profile
|
№6 / 2019
|
|
Bakirov B.A., Zaripova G.R., Akbuldina K.R., Bogdanova Yu.A., Kudlai D.A.
Russian and foreign experience of evaluating adherence to long-term therapy in patients with rheumatic arthritis: review of literature
|
№2 / 2019
|
|
A.P. Rebrov, M.A. Tyapkina, O.G. Karpova
Renal dysfunction and cardiovascular risk in rheumatic arthritis patients
|
№4 / 2018
|
|
N.V. Chichasova, E.V. Igolkina, G.R. Imametdinova, E.L. Nasonov
Curation of rheumatic arthritis patients: modern recommendations and real clinical practice
|
№4 / 2018
|
|
A.M. Lila, E.L. Nasonov, Ju. A. Olyunin, E.A. Galushko
Actual aspects of modern rheumatology
|
№4 / 2018
|
|
L.V. Kondratieva, T.V. Popkova, Ye.L. Nasonov
Prevalence of traditional risk factors for type 2 diabetes mellitus in patients with rheumatoid arthritis
|
№4 / 2017
|
|
Ye.L. Nasonov
Pharmacotherapy of rheumatoid arthritis
|
№4 / 2017
|
|
O.A. Gromova, I.Yu. Torshin, Ye.A. Dibrova, A.V. Gilels, B.I. Demidov
Human placenta hydrolyzates in reconstructive therapy of connective tissue of cartilage and joints
|
№6 / 2016
|
Русский
